Serum concentrations of ampicillin and probenecid and ampicillin excretion after repeated oral administration of a pivampicillin-probenecid salt (MK-356). 1975

H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner

Twenty male volunteers received oral doses (2100, 1050, and 525 mg) of a pivampicillin-probenecid salt in a 1 to 1 molar ratio (MK-356) at 12 hour intervals. After each dose peak serum concentrations of probenecid were observed 2 hours later than peak concentrations of ampicillin. Following the first dose of MK-356 the apparent elimination rate of ampicillin was dose-dependent and did not follow first order kinetics, as it showed a longer apparent half life after a higher dose. An equal dose of MK-356 administered 12 hours later caused an increase in the peak serum ampicillin level greater than expected from the concentration of ampicillin after the preceding dose. In twelve male volunteers who received at random 525 mg of MK-356 or 350 mg of pivampicillin, each three times daily for 4 days, the areas under the ampicillin concentration curve were the same after the first or last dose of either drug. When 2100 or 1050 mg of MK-356 was taken as an initial dose, 30 to 40 per cent of the ampicillin was recovered from urine in the ensuing 12 hours. The results indicate that when at least 400 mg probenecid was coadministered twice daily with 700 mg pivampicillin (MK-356), the peak serum concentrations of ampicillin were increased and its elimination rate slowed following successive doses.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D010917 Pivampicillin Pivalate ester analog of AMPICILLIN. Ampicillin Pivaloyl Ester,Berocillin,Pivamiser,Pivampicillin Hydrochloride,Pivampicillin Monohydrochloride,Pondocillin,Ester, Ampicillin Pivaloyl,Hydrochloride, Pivampicillin,Monohydrochloride, Pivampicillin
D011339 Probenecid The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Benecid,Benemid,Benuryl,Pro-Cid,Probecid,Probenecid Weimer
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner
February 1975, MMW, Munchener medizinische Wochenschrift,
H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner
June 1974, Arzneimittel-Forschung,
H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner
January 1972, Acta tuberculosea et pneumologica Belgica,
H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner
October 1974, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner
January 1974, European journal of clinical pharmacology,
H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner
March 1973, Pediatrics,
H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner
November 1975, Arzneimittel-Forschung,
H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner
January 1973, Chemotherapy,
H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner
July 1989, Drug and therapeutics bulletin,
H G Kampffmeyer, and I Hartmann, and H Metz, and G O Breault, and H R Skeggs, and A E Till, and L Weidner
September 1970, Polski tygodnik lekarski (Warsaw, Poland : 1960),
Copied contents to your clipboard!